Any current/future new fundraising through debt or equity?

The company has successfully completed an IPO and listing on NSE Emerge in September 2023, which has already facilitated significant growth. The board has approved extending debt to its subsidiary, Unihealth Pharmaceuticals Private Limited, to support increased export and distribution activities. There is no explicit mention of any new upcoming fundraising through equity or external debt beyond this approved debt extension to the subsidiary. The company is focusing on organic growth, acquisitions, and an asset-light model by leveraging existing infrastructure for expansion. Capex for the next

Any current/future capex/capital investment/strategic investment?

Current capex plan: INR 25 crores (~INR 2,500 lakhs) over the next two years, mainly for investing in high-end medical equipment rather than infrastructure, following an asset-light model. Focus on expanding bed capacity from 200 to 1000 beds by FY 2025-26, including 300-350 beds targeted in India (Western India) through organic growth and acquisitions. Expansion involves upgrading existing hospitals in Uganda and Nigeria with super specialty services (ophthalmology, infertility, cardiology) by investing in equipment and specialized manpower. Acquisition strategy: Targeting 50-100 bed faciliti

Future growth expectations in sales/revenue/volumes?

Target to increase bed capacity from current 200 beds to around 1,000 beds by FY 2025-26, including 300-350 beds in India. Expansion plans include both organic growth (O&M contracts) and acquisitions, focusing on 50-100 bed facilities. Expect significant revenue growth from adding super specialty services like ophthalmology, infertility, cardiology, and later cancer care. Pharmaceutical product registrations underway; expect multi-fold growth in pharmaceutical exports and sales post-registration by 2025-26. New syringe manufacturing plant in Tanzania to commission by June next year, targeting

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets increasing bed capacity from 200 to 1,000 beds by fiscal year 2025-26, including 300-350 beds in India, which will drive revenue growth. Expansion involves both organic growth (new setups, O&M contracts) and acquisitions (50-100 bed facilities). Investment focus is on equipment and super specialty services (ophthalmology, infertility, cardiology) to enhance EBITDA margins. Overseas business currently contributes over 90% to revenue and profitability; growth in African markets is a priority. Pharmaceutical product registrations underway; once completed (~9-15 months), this w

Current/ Expected Orderbook/ Pending Orders?

The transcript on page 17 does not explicitly mention the current or expected order book or pending orders in specific numbers. However, it highlights ongoing and future business opportunities in Uganda, Nigeria, and Tanzania, including: - Distribution and sales of imported medical goods to government agencies, UN, and other medical centers. - Participation in government and NGO tenders in targeted countries once product registrations are completed, leading to potential multi-fold business increase. Expansion plans include targeting 300+ bed capacity in India with hospital bids, though no

Unihealth HospQ2 FY24Healthcare Services

Unihealth Hosp Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹550.05P/E: 34.1Market Cap: ₹875 CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Target to increase bed capacity from current 200 beds to around 1,000 beds by FY 2025-26, including 300-350 beds in India.
Expansion plans include both organic growth (O&M contracts) and acquisitions, focusing on 50-100 bed facilities.
Expect significant revenue growth from adding super specialty services like ophthalmology, infertility, cardiology, and later cancer care.
Pharmaceutical product registrations underway; expect multi-fold growth in pharmaceutical exports and sales post-registration by 2025-26.
New syringe manufacturing plant in Tanzania to commission by June next year, targeting 5-6 million syringes per month with potential to add infusion sets and other consumables.
Increasing distribution to government agencies and NGOs in African countries, expanding beyond captive use.
Overall, steady volume and revenue growth expected from both hospital expansion and diversified product offerings in India and Africa.

Margin guidance

Category 3

The company targets increasing bed capacity from 200 to 1,000 beds by fiscal year 2025-26, including 300-350 beds in India, which will drive revenue growth.
Expansion involves both organic growth (new setups, O&M contracts) and acquisitions (50-100 bed facilities).
Investment focus is on equipment and super specialty services (ophthalmology, infertility, cardiology) to enhance EBITDA margins.
Overseas business currently contributes over 90% to revenue and profitability; growth in African markets is a priority.
Pharmaceutical product registrations underway; once completed (~9-15 months), this will significantly boost revenue.
Brand recognition is strong in Africa, with increasing brand presence planned in India.
Operating cash flows are solid, supporting capex plans of INR 25 crores over two years.
Expected increase in specialty services and hospital capacities will likely lead to multi-fold revenue and profit expansion.

See what Unihealth Hosp management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company has successfully completed an IPO and listing on NSE Emerge in September 2023, which has already facilitated significant growth.
The board has approved extending debt to its subsidiary, Unihealth Pharmaceuticals Private Limited, to support increased export and distribution activities.
There is no explicit mention of any new upcoming fundraising through equity or external debt beyond this approved debt extension to the subsidiary.
The company is focusing on organic growth, acquisitions, and an asset-light model by leveraging existing infrastructure for expansion.
Capex for the next two years is planned at around INR 25 crores, primarily for equipment investments rather than infrastructure.
Overall, current plans rely on internal accruals, subsidiary debt, and strategic partnerships, with no fresh equity or large debt fundraising announced.

Order book

The transcript on page 17 does not explicitly mention the current or expected order book or pending orders in specific numbers.
However, it highlights ongoing and future business opportunities in Uganda, Nigeria, and Tanzania, including:
- Distribution and sales of imported medical goods to government agencies, UN, and other medical centers.
- Participation in government and NGO tenders in targeted countries once product registrations are completed, leading to potential multi-fold business increase.
Expansion plans include targeting 300+ bed capacity in India with hospital bids, though no condition of exclusivity as consultant.
The company is pursuing both organic growth and acquisitions to increase bed capacity from 200 to 1000 by 2026.
Investment in equipment and super specialty services in existing African facilities is ongoing.
No specific numeric order book or pending order values are disclosed in the available transcript pages.

See what Unihealth Hosp management said on order book — free account, 30 seconds.

Capex plans

Yes

Current capex plan: INR 25 crores (~INR 2,500 lakhs) over the next two years, mainly for investing in high-end medical equipment rather than infrastructure, following an asset-light model.
Focus on expanding bed capacity from 200 to 1000 beds by FY 2025-26, including 300-350 beds targeted in India (Western India) through organic growth and acquisitions.
Expansion involves upgrading existing hospitals in Uganda and Nigeria with super specialty services (ophthalmology, infertility, cardiology) by investing in equipment and specialized manpower.
Acquisition strategy: Targeting 50-100 bed facilities, combined with operating and management (O&M) contracts leveraging existing local infrastructure.
Pharmaceutical division capex involves registering manufacturing plants and drugs in African countries to increase export and distribution, with approvals expected in 9 to 15 months.
Strategic investment in medical travel collaborations with airlines (e.g., Ethiopian Air, Air Tanzania, Myanmar Airways) to boost patient inflow.

Track Unihealth Hosp — get its next earnings analysis in your feed

How does Unihealth Hosp rank vs peers in Healthcare Services?

Pro feature

ThisUnihealth Hosp

Rev 2Mar 3

See where Unihealth Hosp sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Unihealth Hosp rank in Healthcare Services?

Compare Unihealth Hosp against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Unihealth Hosp's management said in earlier quarters

Others in Healthcare Services this season

Vijaya Diagnostic Centre (Q2 FY27)
Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves
Shalby (Q2 FY27)
Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9) . Key investor presentation takeaways from S
Metropolis Healt (Q2 FY27)
Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre
Nephrocare Health Services (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9). Key investor presentation takeaways from Nephrocare Health Services

Compare:vs Apollo Hospitals vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →